However, on-target-off-tumor toxicity appears to be less of a concern in antibody mediated therapy as monoclonal antibody targeting of CA9 has been used for imaging (77) and radio-immunotherapy (78, 79) without significant GI toxicity issues. This evidence concerns the gene CA9 and neoplasm.